Methylprednisolone versus intravenous immunoglobulins in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS): an open-label, multicentre, randomised trial
In this RCT, treatment with methylprednisolone in children with PIMS-TS did not significantly affect the length of hospital stay compared with intravenous immunoglobulins. Intravenous methylprednisolone could be an acceptable first-line treatment in children with PIMS-TS.
In this RCT, treatment with methylprednisolone in children with PIMS-TS did not significantly
affect the length of hospital stay compared with intravenous immunoglobulins. Intravenous
methylprednisolone could be an acceptable first-line treatment in children with PIMS-TS.
